Targeting the High-Risk Patient: Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies

  • Springer Healthcare Independent Medical Education hosted an educational symposium at the European Society of Cardiology Congress (ESC) in London, Sunday 30th August 2015.

    We invite you to view the presentation highlights taken from the expert-led program:

    videoPlay Welcome and opening address
    videoPlay Targeting LDL-c: commonalities and differences among major guidelines
    videoPlay Triglyceride-rich lipoproteins and remnants
    videoPlay Treatment of the high-risk patient: what do we do after statin therapy?
    videoPlay Summary and close
    Christie Ballantyne
    Alberico Catapano
    Børge Nordestgaard
    Wouter Jukema
    Christie Ballantyne

  • Faculty Members

    Christie Ballantyne, (Symposium Chair)
    Professor of Medicine and Chief of the Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine

    Alberico Catapano
    Full Professor of Pharmacology at the University of Milano

    Wouter Jukema
    Professor of Cardiology and Chairman of “Leiden Vascular Medicine” at Leiden University Medical Center

    Børge Nordestgaard
    Chief Physician in Clinical Biochemistry at Copenhagen University Hospital and Professor in Genetic Epidemiology at the University of Copenhagen, Denmark.

  • Chairman’s Address

    It is my pleasure on behalf of the Faculty to welcome you to this EBAC-accredited educational programme entitled Targeting the High-Risk Patient: Evolving Concepts on Optimally Modifying Risk by Lipid-Modulating Therapies. We welcome you to London and hope you will enjoy this highly educational meeting.

    In this symposium, Professor Alberico Catapano will discuss the commonality that all guidelines emphasise the use of a high- efficacy statin in high-risk patients to achieve greater than 50% LDL-c reduction and the controversies over targets. Professor Børge Nordestgaard will then review how the recent genetic data have provided greater insights into triglyceride-rich lipoproteins as risk factors, not risk markers, as well as the recent trial data for triglyceride-lowering therapies. Finally, Professor Wouter Jukema will give a case presentation and review of the treatment approach for a patient with diabetes and chronic heart disease on statin therapy who still has high triglyceride levels.

    We look forward to discussing these points with you during what promises to be a stimulating and informative symposium.

  • Programme

    12:45 – 12:50
    Welcome and opening address
    Christie Ballantyne

    12:50 – 13:05
    Targeting LDL-c: commonalities and differences among major guidelines
    Alberico Catapano

    13:05 – 13:20
    Triglyceride-rich lipoproteins and remnants
    Børge Nordestgaard

    13:20 – 13:40
    Treatment of the high-risk patient: what do we do after statin therapy?
    Wouter Jukema

    13:40 – 13:45
    Summary and close
    Christie Ballantyne